OM
ARRY

Opaleye Management’s Array Biopharma Inc ARRY Stock Holding History

Opaleye Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-305,000
Closed -$1.43M – 36
2014
Q1 		$1.43M Buy
+305,000
New +$1.53M 1.06% 24

Other funds holding ARRY

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Opaleye Management's ARRY Position: Q2 2014 in Review

Opaleye Management sold out of Array Biopharma Inc (ARRY) in Q2 2014, closing a stake of 305,000 shares — an estimated $1.43M sold.

Opaleye Management first reported a position in ARRY in Q1 2014 and held it in 1 quarter. The position peaked at $1.43M in Q1 2014. 129 funds tracked by Wall St. Rank hold ARRY as of Q2 2014.

  • Opaleye Management reported no remaining Array Biopharma Inc position as of Q2 2014 after selling out during the quarter.
  • Opaleye Management sold 305,000 Array Biopharma Inc shares in Q2 2014, an estimated $1.43M.
  • Opaleye Management first reported a position in Array Biopharma Inc in Q1 2014 and held it in 1 quarter.
  • Opaleye Management's Array Biopharma Inc position peaked at $1.43M in Q1 2014.
  • 129 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2014.

Based on Opaleye Management's 13F filing for Q2 2014, filed 14 Aug 2014.